Aethlon Medical, Inc.

Aethlon Medical, Inc. (AEMD) reported a net loss of $2.0 million for the third quarter of fiscal year 2026, ending December 31, 2025. This represents an improvement in operational efficiency compared to the year-to-date net loss of $5.3 million. The company recorded zero revenue for the period, consistent with its clinical-stage status. Total operating expenses were controlled at $2.1 million, driven by payroll expenses of $987K and general administrative costs of $742K. The company strengthened its liquidity position significantly through financing activities, raising $7.7M from equity issuances and warrant exercises. This resulted in a net increase of $1.5M in cash and equivalents, bringing the total cash position to $7.0M. The balance sheet reflects total assets of $8.1M against total liabilities of $1.3M, resulting in stockholders' equity of $6.7M. The company continues to fund operations through capital raises while advancing its medical technology development.

Key Takeaways